News

ClinicalTrials.gov: peptide AND aging

ClinicalTrials.gov lists a 90-day randomized, controlled pilot trial of combination gerotherapies as completed. The study was designed to enroll up to 30 participants across three arms to explore longevity-related outcomes; the excerpt provides no results.

ClinicalTrials.gov: peptide AND aging

A study listed on ClinicalTrials.gov is enrolling by invitation to evaluate blood-based measures of organ-specific biological age, particularly in the brain. Researchers aim to examine how these measures relate to established clinical health indicators and respond to treatment with tirzepatide.

ClinicalTrials.gov: peptide AND aging

A ClinicalTrials.gov listing marked completed describes research on growth hormone’s effects on immune function in healthy men aged 25–50. The protocol includes three studies, but the provided excerpt reports no results.

ClinicalTrials.gov: peptide AND aging

A ClinicalTrials.gov-listed study is enrolling by invitation to assess whether geroprotective agents and a peptide-containing skin serum lower measured biological age. Researchers will use gene-activity measurements in skin and blood and assess safety and tolerability; the excerpt reports no results.

ClinicalTrials.gov: peptide AND aging

A ClinicalTrials.gov listing describes a randomized, double-blind, placebo-controlled trial of Vicia faba L.-derived peptides combined with resistance training in approximately 100 adults aged 60 or older. The study is enrolling by invitation and will assess physical, cognitive, and quality-of-life outcomes.

ClinicalTrials.gov: peptide AND aging

A ClinicalTrials.gov listing reports that a study of tirzepatide in post-menopausal women with obesity is recruiting. The study aims to assess effects on menopausal vasomotor symptoms and measures of biological aging.

ClinicalTrials.gov: peptide AND aging

The ClinicalTrials.gov study “Prandial Metabolic Phenotype in Adults” is active but not recruiting. Investigators aim to measure whole-body metabolism in older adults to examine age-related changes in protein turnover and amino acid metabolism.

ClinicalTrials.gov: elamipretide

A ClinicalTrials.gov listing reports that a study of elamipretide focused on healthy aging and physical function is recruiting. The study plans to enroll 30 participants, with a four-week intervention period followed by two weeks of follow-up.

ClinicalTrials.gov: elamipretide

ClinicalTrials.gov lists a completed Phase 2 study of MTP-131 (elamipretide) involving 41 elderly participants with previous evidence of mitochondrial dysfunction. The randomized, double-blind, placebo-controlled trial evaluated effects on hand skeletal muscle energetics or muscle performance; the excerpt provides no results.